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Abstract
The properties of control and 370Asn -- Ser glucocerebrosidase,
the frequently encountered mutated form of the enzyme in type
1 Gaucher disease, were studied in vitro as well as in situ.
The catalytic properties of purified 37Asn -* Ser glucocere-
brosidase were highly dependent on the assay conditions. The
enzyme was deficient in activity towards substrate and in reac-
tivity with the irreversible inhibitor conduritol B-epoxide
(CBE) when activated by the bile salt taurocholate. In the pres-
ence of more physiological activators, the lysosomal activator
protein saposin C and phosphatidylserine, the 37OAsn -- Ser
enzyme was near normal in kinetic properties at pH values
5, but not at higher pH.
In intact fibroblasts, the enzymic activity of the 370Asn
Ser glucocerebrosidase and its reactivity with CBEwere found
to be clearly deficient. However, in intact lymphoblasts from
the same patients, the behavior of the mutant enzyme was near
normal. The catalytic efficiency of 370Asn -- Ser glucocerebro-
sidase in situ was also found to be highly pH dependent. When
intact lymphoblasts were cultured in the presence of permeant
weak bases, which increase the pH of acidic intracellular com-
partments, the catalytic efficiency of the mutant enzyme, as
assessed by its reactivity with CBE, became markedly im-
paired.
Our findings indicate that the intralysosomal pH in the in-
tact cell can be expected to have a critical influence on the
activation state of 37OAsn -- Ser glucocerebrosidase and its abil-
ity to hydrolyse substrate. This phenomenon may partly un-
derly the marked heterogeneity in clinical manifestation of
Gaucher disease among patients with this mutated form of glu-
cocerebrosidase. (J. Clin. Invest. 1993. 91:1167-1175.) Key
words: conduritol B-epoxide - glucosylceramide lipidosis * lyso-
somal storage disorder * saposin C
Introduction
Gaucher disease (glucosylceramidosis) is a recessively in-
herited lysosomal storage disorder in which the activity of glu-
cocerebrosidase (EC 3.2.1.45) is deficient. The clinical mani-
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festation of the disease is very heterogeneous with respect to age
of onset and neurological involvement. In patients with the
most frequently encountered form, type 1, the clinical presenta-
tion may vary from cases with severe splenomegaly and bone
deterioration to cases without clear clinical complications ( 1).
Type 2 and type 3 Gaucher disease patients develop neurologi-
cal complications in infancy or childhood, respectively ( 1).
Gaucher disease is genetically heterogeneous. Several muta-
tions in glucocerebrosidase have been identified (2-6), and it
has become clear that patients may have either two identical or,
more generally, two different mutant glucocerebrosidase alleles
(see e.g., references 7 and 8). Most type 1 Gaucher disease
patients carry at least one copy of a mutant glucocerebrosidase
allele in which a mutation at position 1,226 in the cDNAleads
to substitution of G for A (cDNA nucleotides are numbered
starting with the upstream ATGat number 1 [9]). This results
in a substitution of serine for asparagine at amino acid position
370 in the mature protein (8, 10, 11 ). The 370Asn -- Ser gluco-
cerebrosidase is present in normal amounts ( 12-15). In vitro,
this enzyme is only poorly active under most conditions; how-
ever, when activated at acidic pH by negatively charged phos-
pholipid and the natural lysosomal activator protein saposin C,
formerly referred to as sphingolipid activator protein 2 (for a
review, see reference 16), its activity is near normal ( 17). An-
other frequently encountered form of mutated glucocerebrosi-
dase has a C for T substitution at nucleotide position 1,448,
resulting in a proline for leucine substitution at position 444 in
the mature protein. This mutation has been detected in various
phenotypes of Gaucher disease. Most patients who are homo-
zygous for this mutation develop a neuronopathic course of the
disease (7, 11, 18-20). The 4"Leu -* Pro glucocerebrosidase
results in reduced enzyme stability ( 15-21 ). In a third com-
monly encountered allele, a Ginsertion in the glucocerebrosi-
dase gene at cDNAposition 84 results in production of a trun-
cated protein (22).
The consequences of the 370Asn -o Ser substitution for cata-
lytic efficiency of glucocerebrosidase in situ are not yet fully
understood. It has previously been observed by us that the state
of activation of 370Asn Ser glucocerebrosidase, and con-
comitantly its catalytic efficiency, differs in homogenates of
fibroblasts and lymphoblasts obtained from the same type 1
Gaucher disease patients (23). Wehave now studied the prop-
erties of glucocerebrosidase in intact fibroblasts and lympho-
blasts. First, the degradation of a fluorescent analogue of gluco-
cerebroside by intact cells was measured. Second, the reactivity
of glucocerebrosidase with the irreversible inhibitor conduritol
B-epoxide (CBE)' was assessed. This inhibitor is analogous in
1. Abbreviations used in this paper: CBE, conduritol B-epoxide; C6-
NBDglucosylceramide, 6-[N-7-nitrobenz-2-oxa-1,3 diazol-4-yl-ami-
nocaproyl ] sphingosyl 3-D-glucoside; 4-MU-,B-glucoside, 4-methylum-
belliferyl-fl-D-glucoside.
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structure to the transition state of gluconolactone formed dur-
ing hydrolysis of glucocerebroside. In contrast to the natural
transition state compound, the epoxide is able to form a cova-
lent bond with an aspartic acid group in the catalytic site, thus
irreversibly inhibiting the enzyme (2, 24). It has elegantly been
shown by Bieberich and Legler (25) that CBE rapidly enters
lysosomes in intact cells and effectively inhibits the enzyme in
situ.
Our investigation revealed differences between properties
of glucocerebrosidase in intact fibroblasts and in intact lympho-
blasts from type 1 Gaucher disease patients with 370Asn -- Ser
glucocerebrosidase. The possible role of the natural activator
protein saposin C and lysosomal pH in this connection was
investigated. The results are reported here, and the implica-
tions are discussed.
Methods
Materials. CBE was purchased from Biomol Research Laboratories
(Philadelphia, PA), sodium taurocholate grade A was purchased from
Calbiochem (San Diego, CA); and phosphatidylserine, and 4-methyl-
umbelliferyl-#-D-glucoside (4-MU-3-glucoside) was purchased from
Sigma Immunochemicals (St. Louis, MO). C6-NBD glucosylceramide
(6-[N-7-nitrobenz-2-oxa- 1,3 diazol-4-yl-aminocaproyl] sphingosyl f-
n-glucoside) was a kind gift from Dr. G. Schwarzmann (University of
Bonn, Bonn, Germany). All other chemicals were of the purest grade
commercially available.
Cell lines of Gaucher disease patients. Properties of glucocerebrosi-
dase were studied in cultured skin fibroblasts and EBV transformed B
lymphocytes (lymphoblasts) from Gaucher disease patients with a de-
fined glucocerebrosidase genotype; i.e. genotypes 370Asn Ser/ 370Asn
Ser, "4Leu -* Pro/44Leu -- Pro and 370Asn -* Ser/4"Leu -* Pro.
Fibroblasts were obtained by skin biopsies and lymphoblasts were ob-
tained by transformation of peripheral blood B lymphocytes with EBV
(23, 26). The cells were cultured in RPMI 1640 containing 10% (by
volume) FCS and bicarbonate with 5% CO2 in the gas phase. The
glucocerebrosidase genotype of the patients was determined by allele-
specific oligonucleotide hybridization (26). In the case of patient C
(Table I), it has not as yet been excluded that the mutated 44Leu -*
Pro allele contains additional mutations (also referred to as complex
pattern alleles). The cell biological consequences of the 44Leu -0 Pro
mutation and one of the complex pattern alleles are known to be simi-
lar; i.e. the production of a rapidly degraded glucocerebrosidase ( 15).
The Gaucher disease patients homozygous or heterozygous for the
370Asn -- Ser allele varied markedly in severity of nonneuronopathic
manifestation of the disorder. The patients homozygous for the 44Leu
-- Pro allele had developed neurological complications already in in-
fancy (type 2) or only in childhood (type 3).
Consistent with earlier findings, it was noted using PAGEin the
presence of sodium dodecyl sulphate followed by Western blotting
(27), that the amount of glucocerebrosidase antigen was normal in
fibroblasts of patients homozygous for the 370Asn -- Ser allele (i.e., type
1 patients) and very strongly reduced in fibroblasts of patients homozy-
gous for the 44Leu -- Pro allele (i.e., type 2 and 3 patients). In cells
from patients who were genetic compounds carrying both alleles, inter-
mediate amounts of cross-reactive glucocerebrosidase were detected.
Preparation of antisera. A monospecific rabbit antiserum to hu-
man placental glucocerebrosidase was prepared as described (28). A
monospecific rabbit antiserum to saposin C was prepared as described
(29).
Immunoaffinity chromatographic purification of glucocerebrosi-
dase. Glucocerebrosidase was purified from various materials by immu-
noaffinity chromatography with immobilized antiglucocerebrosidase
monoclonal antibodies 8E4 and 2C7 as immunosorbens exactly as de-
scribed previously (30).
Table I. Relative Specific Activity of Glucocerebrosidase
Immunopurified from Cultured Skin Fibroblasts of Gaucher
Patients
Relative specific activity measured in the
presence of
Genotype Patient Taurocholate/Triton PS/saposin C
370/370 A 16, 14 77, 88
B 15,8 79, 84
370/444 C 21, 20 92, 87
D 22 89
444/444 E 81, 73 86, 82
F 85 81
Control (n = 4) 88-115 92-107
Identical amounts of cross-reactive glucocerebrosidase in preparations
from cultured skin fibroblasts of control subjects and Gaucher disease
patients were bound in a microtiter plate in which monoclonal anti-
human glucocerebrosidase antibody 8E4 was immobilised, as de-
scribed in Methods. The relative specific activity is the enzymic ac-
tivity per amount of cross-reactive glucocerebrosidase in a prepara-
tion from a cell line of a Gaucher disease patient as percentage of the
mean value for preparations from four different control fibroblast
cell lines. The activity of bound glucocerebrosidase was determined
with two different assay mixtures, each well containing 150,pl assay
mixture. The reaction was stopped by addition of 100 pl 1 Mgly-
cine-NaOH, pH 10.6. The taurocholate/Triton assay mixture con-
tained 5 mM4-MU-0-glucoside, 0.1 %(by volume) Triton X- 100,
0.5% (mass/vol) sodium taurocholate, 100:200 mMcitric acid/so-
dium phosphate, pH 5.0; and the phosphatidylserine/saposin C assay
mixture contained 5 mM4-MU-/3-glucoside, 10,qg/ml phosphatidyl-
serine, 2.4 ,g/ml saposin C preparation, 100:200 mMcitric acid/so-
dium phosphate, pH 5.0. The specific activity of control glucocere-
brosidase immobilized to monoclonal antibody 8E4 was 1.8 and 1.4
nmol/h per mg protein when measured in the presence of taurocho-
late/Triton and PS/saposin C, respectively. 370, 370Asn - Ser allele;
444, 44Leu -. Pro allele.
Purification of saposin C. The activator protein was purified ac-
cording to the procedure described (31).
Assessment of activator protein level. The level of activator protein
was determined by a functional test as described (12).
The assay of glucocerebrosidase with 4-MU-13-glucoside as sub-
strate. Fibroblasts were harvested by trypsinisation and lymphoblasts
by centrifugation. The cells were washed in isotonic PBSand homoge-
nized as indicated in the text. The contribution of lysosomal glucocere-
brosidase to the total ,B-glucosidase activity was determined using CBE.
Enzyme preparations were simultaneously preincubated for 5 min
without CBE, or with 5 mMCBEto ensure that all glucocerebrosidase
was inactivated by the irreversible inhibitor, and subsequently ,B-gluco-
sidase activity was measured in the absence and presence of 1 mMCBE
under the conditions indicated in the text. The CBE-inhibitable 3-glu-
cosidase activity is caused by the lysosomal glucocerebrosidase (31 ).
Protein was determined as described by Lowry et al. (32) with BSAas
standard.
Measurement of relative specific activity ofglucocerebrosidase. Pre-
vious studies have shown that monoclonal anti-( human glucocerebro-
sidase) antibody 8E4 has the same binding affinity for control, 370Asn
-- Ser substituted and 44Leu -- Pro substituted glucocerebrosidase
(12, 13, 15). Thus, identical amounts of various types of glucocerebro-
sidase will be bound to a specific amount of immobilized monoclonal
antibody 8E4 when the immunosorbens is saturated by incubation
with an excess of an enzyme preparation. If the enzyme preparation
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consists of a mixture of two forms of glucocerebrosidase, the bound
glucocerebrosidase will be a comparable mixture. These binding char-
acteristics of the monoclonal antibody 8E4 allow a simple analysis of
the specific activity of mutated glucocerebrosidase per amount of en-
zyme protein as described previously ( 12). Briefly, identical amounts
of antiglucocerebrosidase monoclonal antibody 8E4 were immobilized
to wells of a microtiter plate. The wells were incubated with enzyme
preparations containing an excess of glucocerebrosidase antigen. The
activity of bound glucocerebrosidase was measured with the fluoro-
genic 4-MU-3-glucoside as substrate as described in the legend of Table
I. Fluorescence in the wells of the microtiter plate was determined
(Fluoroscan; Flow Laboratories Inc., McLean, VA) with excitation at
366 nmand emission at 450 nm.
Measurement of hydrolysis of C6-NBD glucosylceramide in intact
cells. C6-NBD glucosylceramide was complexed with BSAas described
(13). Cells were incubated for 24 h at 370C with 5 juM lipid-BSA
complex in the absence or presence of excess CBE. The cells were har-
vested, and lipids were extracted and separated by thin layer chromatog-
raphy. The fluorescent lipids were scraped off, extracted, and quanti-
fied fluorimetrically as described ( 13 ).
Immuno-electron microscopy. Cultured human skin fibroblasts and
EBV-lymphoblasts were fixed and prepared for immunogold labeling
and electron microscopy following the procedure described for fibro-
blasts (33). Frozen cell samples were cryosectioned and immunola-
beled, and examined using a transmission electron microscope (model
300; Phillips Electronic Instruments Co., Mahwah, NJ) at an accelerat-
ing voltage of 60 kV.
Results
Enzymic properties of purified glucocerebrosidase
Glucocerebrosidase was purified by immunoaffinity chroma-
tography from cultured skin fibroblasts. The recovery of en-
zyme in monomeric form (31 ) was always > 70% on the basis
of enzymic activity as measured in the presence of taurocho-
late.
Relative specific activity. The enzymic activity per amount
of cross-reactive glucocerebrosidase related to that of control
enzyme (i.e., the relative specific activity) was determined for
enzyme preparations from fibroblasts from various types of
Gaucher disease patients (see Table I). Whenmeasured in the
presence of taurocholate and Triton X- 100, the relative specific
activity of glucocerebrosidase in preparations of cells of pa-
tients homozygous for the 370Asn -- Ser allele is abnormally
low, and that of enzyme in preparations from cells of patients
homozygous for the "4Leu -> Pro allele is close to normal. The
relative specific activity of glucocerebrosidase in preparations
from cells of patients who are genetic compounds for the
370Asn -- Ser and "4Leu Pro alleles is also low, suggesting
that they contain predominantly 370Asn -- Ser glucocerebrosi-
dase molecules.
When bound glucocerebrosidase is measured in the pres-
ence of phosphatidylserine and activator protein the relative
specific activity of enzyme in the preparations from fibroblasts
of all the patients is near normal (see Table I). In other words,
under these conditions, the "70Asn -* Ser glucocerebrosidase is
normalized.
The amount of cross-reactive glucocerebrosidase can be es-
timated by comparing the data for relative specific activity with
values for specific activity in the corresponding cell extracts. In
this way, it was calculated that the concentration of glucocere-
brosidase antigen is 80-100% in fibroblasts from patients with
genotype 370Asn -. Ser/370Asn -* Ser, < 10% in cells from
patients with genotype "4Leu -- Pro/444Leu -- Pro and
- 30% in cells from patients carrying both alleles.
Inactivation by CBE. The irreversible inhibition of gluco-
cerebrosidase by CBE was determined for enzyme purified
from fibroblasts of individuals with different glucocerebrosi-
dase genotypes. Fig. 1 A shows the results when enzyme prepa-
rations were incubated with inhibitor in the presence of tauro-
cholate and Triton X- 100, and enzyme activity was subse-
quently determined under the same conditions. The
glucocerebrosidase purified from fibroblasts of the patient ho-
mozygous for the "4Leu -* Pro allele was inactivated in a man-
ner similar to control enzyme, but the inactivation of enzyme
purified from cells of the patient homozygous for the 370Asn -*
Ser allele was very slow. The inactivation of enzyme purified
from cells of the genetic compound proceeded with interme-
diate kinetics. Whenthe enzyme preparations were incubated
with inhibitor in the presence of phosphatidylserine and activa-
tor protein at pH 5.0, and the enzyme activity was determined
under the same condition a different picture was obtained (see
Fig. 1 B). Under these conditions, the behavior of glucocere-
brosidase purified from fibroblasts of all the Gaucher disease
patients was not clearly different from that of control enzyme.
This suggests that in the presence of phospholipid and activator
protein the 370Asn -* Ser glucocerebrosidase is not only 'nor-
malized' in activity towards substrate, but also in reactivity
with CBE.
Analogous findings to the results presented in Table I and
Fig. 1 were made for glucocerebrosidase purified from urine
samples, spleens, and lymphoblasts from type I Gaucher dis-
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Figure 1. Inactivation of purified glucocerebrosidase by conduritol
B-epoxide. Glucocerebrosidase was purified from fibroblasts of indi-
viduals with known glucocerebrosidase genotype by immunoaffinity
chromatography as described previously (30). The purified enzyme
was preincubated at room temperature for the times indicated with
25 ,M CBEin 100:200 mMcitric acid/sodium phosphate buffer, pH
5.0, containing 0.1% (mass/vol) BSAand 10% (by volume) ethylene
glycol. The preincubation mixture furthermore contained either 0.1%
(by volume) Triton X-l00 and 0.5% (mass/vol) sodium taurocholate
(A) or 10 ,g/ml phosphatidylserine and 2.4 .g/ml saposin C prepa-
ration (B). Subsequently, the enzyme preparation was diluted 10-fold
in preincubation mixture from which CBEwas omitted and to which
5 mM4-MU-f3-glucoside was added. The activity is expressed as a
percentage of that found without preincubation. The results of a typ-
ical experiment are shown. Similar results were obtained in three to
five other experiments and with different batches of CBE. The values
in parentheses indicate the specific activity of immunopurified gluco-
cerebrosidase (nanomoles per hour per milligram of protein) in the
presence of taurocholate/Triton X-100. o, Control (2.8); ., 370Asn
-* Ser/3"0Asn -1 Ser (0.21 ); A, 3"0Asn -. Ser/4"Leu -v Pro (0.31 );
A, "4Leu A Pro/"4Leu -* Pro (2.0).
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served between enzyme preparations from the various sources
examined.
It is of importance to note that the reactivity of glucocere-
brosidase with CBE is to some extent a good reflection of the
activity of the enzyme towards substrate. This was also ob-
served when membrane suspensions were tested instead of
pure enzyme preparations.
Enzymic properties of glucocerebrosidase in intact
fibroblasts and lymphoblasts
Activity towards substrate. The glucocerebrosidase activity in
cultured fibroblasts and lymphoblasts from type 1 Gaucher
disease patients and control subjects was determined by load-
ing cells with C6-NBD glucosylceramide as described in Meth-
ods. Recently we established the existence of a nonlysosomal
glucocerebrosidase activity in cells that is insensitive to CBE.
The properties of the nonlysosomal glucocerebrosidase, which
is not deficient in Gaucher disease materials, are to be de-
scribed in a separate publication. To allow discrimination be-
tween the lysosomal (CBE-sensitive) and nonlysosomal (CBE-
insensitive) glucocerebrosidase cells were pretreated with and
without an excess of CBE. The lysosomal glucocerebrosidase
activity was determined as the CBE-inhibitable hydrolysis of
C6-NBD glucosylceramide (Table II). The residual activity in
fibroblasts of patients with the 370Asn -* Ser allele was always
less than that in lymphoblasts from the same patients.
Inactivation by CBE. The kinetics of the irreversible inhibi-
tion of glucocerebrosidase upon incubation of intact cells with
CBE was examined (Fig. 2). Glucocerebrosidase in control
fibroblasts and in "4Leu -- Pro/"4Leu -> Pro fibroblasts was
clearly inactivated more rapidly than the enzyme in 370Asn ->
Ser/370Asn -> Ser fibroblasts when enzyme activity was subse-
quently measured either in the presence of taurocholate and
Triton X- 100 (Fig. 2 A) or in the presence of phosphatidylser-
ine and activator protein at acid pH (Fig. 2 B). In 370Asn -o
Ser/44Leu -> Pro fibroblasts, the inactivation of glucocerebro-
sidase appeared to be more rapid when the activity was subse-
quently measured in the presence of taurocholate and Triton
Table II. Glucocerebrosidase Activity In Situ towards C6-NBD
Glucosylceramide in Fibroblasts and Lymphoblasts from a
Control Subject and a Type I Gaucher Disease Patient
Percent conversion of C6-NBD glucosylceramide
to ceramide + sphingomyelin in
Fibroblasts Lymphoblasts
CBE- CBE-
Cells from -CBE +CBE Inhibitable -CBE +CBE Inhibitable
Control subject 60 21 39 26 13 13
Gaucher patient 35 29 6 21 12 9
Cells grown in RPMI 1640 culture medium with 5% CO2 in the gas
phase were preincubated with or without 100 ,M CBEfor 24 h at
37°C. Next, C6-NBD glucosylceramide/BSA (5 MM:5 ,uM) was added.
After 24 h at 37°C, the cells were extensively washed and the
NBD-lipids were extracted and analysed using thin layer chromatog-
raphy as described in Methods. Glucocerebrosidase activity is ex-
pressed as the percent conversion of C6-NBD glucosylceramide to C6-
NBDceramide and C6-NBD sphingomyelin. Fluorescence in other
lipids was always <4%. Results of one experiment are shown; similar











Figure 2. Inactivation of glucocerebrosidase in intact fibroblasts by
conduritol B-epoxide. Cells were preincubated in culture medium for
different periods of time with 100 ,uM CBE. After harvesting and
washing with PBS, the fibroblasts were homogenized in 50 mMpo-
tassium phosphate, pH 6.5, containing 0.25% (by volume) Triton
X-100. f-Glucosidase activity was determined with 5 mM4-MU-f-
glucoside as substrate either in 100:200 mMcitric acid/sodium
phosphate, pH 5.2, 0.1% (by volume) Triton X-100 and 0.2%
(mass/vol) sodium taurocholate (A) or in 100:200 mMcitric
acid/sodium phosphate, pH 5.0, 10 Ag/ml phosphatidylserine, and
2.4 Ag/ml saposin C preparation (B). The results of a typical experi-
ment are indicated. Similar data were obtained in at least two inde-
pendent experiments. o, Control; ., 370Asn -- Ser/370Asn -- Ser; A,
170Asn Ser/44Leu -- Pro; A, 44Leu -- Pro/4"Leu -* Pro.
X- 100 (Fig. 2 A) than when it was measured with phosphati-
dylserine and activator protein (Fig. 2 B). This apparent dis-
crepancy results from the fact that with activator protein and
phosphatidylserine, one measures predominantly 370Asn --
Ser enzyme, which is slowly inactivated, whereas in the pres-
ence of taurocholate and Triton X- 100, 44Leu -> Pro enzyme
contributes significantly to the total activity.
Comparison of diferent cell types. Cultured fibroblasts and
lymphoblasts were incubated with CBEfor different periods of
time, and subsequently, enzymic activity of glucocerebrosidase
was measured in the presence of taurocholate and Triton
X-l00.
Table III shows again that lysosomal glucocerebrosidase in
intact fibroblasts from patients with the 370Asn -- Ser allele was
clearly less sensitive to inhibition by CBEcompared to enzyme
in corresponding cells of a control subject and a patient homo-
zygous for the 44Leu -> Pro glucocerebrosidase allele. How-
ever, glucocerebrosidase in cultured lymphoblasts from a con-
trol subject, a patient homozygous for the codon 370 substitu-
tion, and a patient with both the codon 370 and codon 444
substitutions was comparably inactivated by CBE. This cell-
type-specific difference between fibroblasts and lymphoblasts
was also observed in three type 1 Gaucher disease patients with
one allele with the codon 370 mutation and an as yet unidenti-
fied mutated allele (not shown).
Immunocytochemical analysis of glucocerebrosidase and
activator protein saposin C in cultured cells
The apparent difference in glucocerebrosidase activity in intact
lymphoblasts and fibroblasts could, in principle, be caused by a
relatively higher concentration of activator protein in lyso-
somes of lymphoblasts. To test this possibility, the relative in-
tralysosomal concentrations of glucocerebrosidase and activa-
tor protein in fibroblasts and lymphoblasts were studied by
immunoelectron microscopy using specific antisera. Fig. 3
shows some examples of double-labeling of glucocerebrosidase
and saposin in lysosomes in fibroblasts and lymphoblasts from
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Table III. Inactivation of Glucocerebrosidase in Intact Cells by
Conduritol B-Epoxide
Activity nmol/h per
mg protein in CBE-inhibitable activity (percent
nonpreincubated of that in nonpreincubated cells)
cells after preincubation with CBEfor
Cell type -CBE +CBE 10 20 40 60
min
Fibroblasts
Control 384.2 1.0 80 66 45 30
370/370 37.8 0.7 95 87 79 68
370/444 20.7 0.7 90 81 64 52
444/444 17.2 0.4 82 69 48 32
Lymphoblasts
Control 17.1 0.4 75 55 29 16
370/370 1.5 0.3 80 63 32 21
370/444 1.2 0.3 78 59 33 17
Cells grown in RPMI 1640 culture medium containing 10% (by vol-
ume) FCS with 5% CO2 in the gas phase were incubated at 370C
with 100 AMCBEfor different periods of time, washed extensively at
40C with PBS to remove excess inhibitor and harvested. Next, the
cells were homogenized in 50 mMpotassium phosphate, pH 6.5,
containing 0.25% (by volume) Triton X- 100. f-Glucosidase activity
was measured with 5 mM4-MU-3-glucoside as substrate in 100:200
mMcitric acid/sodium phosphate (pH 5.2) containing 0.1% (by vol-
ume) Triton X-100 and 0.2% (mass/vol) sodium taurocholate. At
each preincubation time point, enzyme activity was measured in the
presence of 1 mMCBEin one sample and in the absence of CBEin
a parallel sample. Enzyme activity was related to total cellular protein.
The CBE-inhibitable enzymic activity at each time point is expressed
as percentage of that in cells not preincubated with inhibitor. The re-
sults of a typical experiment are shown. Analogous results were
obtained in at least three independent experiments. 370, "0Asn -
Ser allele; 444, 44Leu -- Pro allele.
a control subject and a patient with the genotype 370Asn -
Ser/44Leu Pro. Quantification of the differently sized gold
particles in lysosomes shows that the ratio of labeled activator
protein to labeled glucocerebrosidase is not significantly differ-
ent in fibroblasts and lymphoblasts of the control subject and
the Gaucher disease patient (Table IV). The amount of activa-
tor protein was also quantified by means of a functional test in
which the ability of denatured protein preparations from differ-
ent cell types to activate purified glucocerebrosidase was mea-
sured. As shown in Table V, the amount of activator protein
was greater in fibroblasts than in lymphoblasts, but there was
no difference between control and Gaucher fibroblasts, or be-
tween control and Gaucher lymphoblasts. Thus, the apparent
difference in properties of glucocerebrosidase in lymphoblasts
and fibroblasts from patients with 370Asn Ser glucocerebro-
sidase cannot simply be attributed to a higher amount of intra-
lysosomal activator protein in the lysosomes of the former
cells.
Effect of pH on activity of3'0Asn -* Ser glucocerebrosidase
Pure enzyme. The influence of pH on enzymic activity of puri-
fied splenic 370Asn -> Ser glucocerebrosidase and control en-
zyme was studied using acetate and citric acid/sodium phos-
phate buffers in the pH range 4.0-6.0. Fig. 4 A shows that the
activity of 370Asn -* Ser glucocerebrosidase in the presence of
activator protein and phospholipid has a very sharp pH opti-
mum. At pH values > 5.4 in acetate buffer and > 5.2 in citric
acid/sodium phosphate buffer, the mutated enzyme is mark-
edly reduced in specific activity. It was noted that in the pres-
ence of higher amounts of activator protein, the specific activ-
ity of 370Asn -- Ser glucocerebrosidase was also close to normal
at pH values between 4.3 and 5.0, but not at pH values > 5.0
(not shown; see also [17]). It appears that the 370Asn -) Ser
substitution in glucocerebrosidase leads to an increased pH de-
pendency of the enzyme with respect to activation by activator
protein. Particularly at higher pH values, the mutated enzyme
is poorly activated by saposin. Fig. 4 B shows that also the
reactivity of 370Asn -* Ser glucocerebrosidase with CBE is ex-
traordinarily pH dependent in the presence of activator protein
and phospholipid. At higher pH values, the mutated enzyme is
dramatically less sensitive for CBE-induced inactivation com-
pared to control enzyme.
Similar results to those presented in Fig. 4 were obtained
with enzyme isolated from fibroblasts and lymphoblasts from
patients homozygous for the 370Asn Ser allele. Furthermore,
370Asn -- Ser glucocerebrosidase isolated from 3T3 fibroblasts
transfected with site-directed mutagenized human glucocere-
brosidase cDNA ( 15) showed a comparable pH dependency
(not shown).
Manipulation of intralysosomalpH with weak bases. Intact
fibroblasts and lymphoblasts were exposed to NH4Cl, a weak
base, to increase the intralysosomal pH, as described by Oh-
kuma and Poole (34). These authors have shown that in
mouse macrophages addition of increasing concentrations of
NH4Cl leads to a concomitant increase in pH of intracellular
acidic compartments (including lysosomes), as monitored by
the extent of quenching of the fluorescence of endocytosed
dextran-fluorescein isothiocyanate. For instance, on addition
of 10 mMNH4Cl, the pH of such compartments increases
from - 4.8 to - 6.2. Fig. 5 shows that with increasing
amounts of NH4Cl, glucocerebrosidase in cells becomes less
sensitive to inactivation by CBE, as would be expected from the
results of Fig. 4 B. This effect of NH4Cl is reversible (not
shown). It should be noted that in the absence of NH4Cl gluco-
cerebrosidase is much more effectively inactivated by CBEin
Gaucher disease lymphoblasts than in Gaucher disease fibro-
blasts. However, at increasing concentrations of NH4C1, the
rate of inactivation of glucocerebrosidase in lymphoblasts re-
sembles that in fibroblasts from the same Gaucher disease pa-
tient. Similar observations were made using methylamine (not
shown).
The findings presented in Figs. 4 and 5 suggest that the
intralysosomal pH to which glucocerebrosidase is exposed
might on the average be lower in cultured lymphoblasts than in
fibroblasts. As an approximate measure of the pH in lysosomes
(and other acidic compartments), we measured the accumula-
tion of radioactively labeled weak base chloroquine (35). We
observed that about seven times more radioactively labeled
chloroquine was trapped by lymphoblasts than by fibroblasts
when related to the amount of glucocerebrosidase present in
the two cell types, whereas the immunogold labeling studies
suggest that the concentration of glucocerebrosidase is about
twice as high in lysosomes of fibroblasts than of lymphoblasts
(see Table IV). This suggests that the average intralysosomal
pH is higher in fibroblasts than in lymphoblasts.
Assessment of activation state ofglucocerebrosidase. When
control cells are homogenized in detergent-free buffer, a pro-
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Table IV. Quantification of Gold Labeling of Glucocerebrosidase and Saposin C in Lvsosomal Structures in Fibroblasts
and Lymphoblasts from a Control Subject and a Type I Gaucher Patient
Number of gold particles/lysosome in fibroblasts Number of gold particles/lysosome in lymphoblasts
Cell line Antigen Mean±SEM n Range Mean±SEM n Range
Control 3-Glu 8.1±1.2 44 0-34 3.9±0.5 83 0-31
Saposin C 11.6±2.1 43 0-51 5.4±0.7 84 0-30
Saposin C/f-Glu 1.61±0.28 38 0-9 2.00±0.37 69 0-18
Gaucher f-Glu 6.0±0.9 20 0-15 2.5±0.7 33 0-16
Saposin C 9.1±1.4 20 1-22 5.8±1.0 33 0-29
Saposin C/3-Glu 2.04±0.43 19 0-7 2.98±1.10 25 0-29
For experimental details, see the legend to Fig. 3. Lysosomal structures present in electron micrographs of a typical immunolabeling experiment
were quantified. The number of lysosomal structures analysed is indicated in the table. 3-Glu, glucocerebrosidase.
portion of glucocerebrosidase remains in activated form, as
reflected by a high ratio of enzymic activity measured in the
absence of additional activators compared to that measured in
the presence of taurocholate (see [23]). The bile salt abolishes
any original activation of glucocerebrosidase and activates fully
all enzymes present (23). Table VI shows that the activity in
the absence of activator is relatively higher in a homogenate of
lymphoblasts than that in a homogenate of fibroblasts. When
the cells are pretreated with NH4C1 to increase the pH of intra-
cellular acidic compartments (see above), this difference dis-
appears and glucocerebrosidase is only poorly active in the ab-
sence of additional activator in homogenates from both cell
types. This finding supports the assumption that on the aver-
age, glucocerebrosidase is present in a more activated state in
intact lymphoblasts than in fibroblasts because of an intralyso-
somal pH difference.
Some of our findings are consistent with those of earlier
studies. First, it has been reported by Grabowski and co-
workers (36, 37) that the mutant form of glucocerebrosidase in
Ashkenazi Jewish type 1 Gaucher disease patients referred to as
group B mutant enzyme is less efficiently inactivated by CBE
than control enzyme either in fibroblast extracts or in partially
purified splenic preparations. It is now almost certain that
group B mutant enzyme is identical to the 370Asn -- Ser gluco-
cerebrosidase (2). Second, it has been reported that glucocere-
brosidase in intact fibroblasts from Ashkenazi Jewish Gaucher
disease type 1 patients was less efficiently inactivated by CBE
compared to enzyme in cells from control subjects and from
other Gaucher disease patients (36). Thus, in the studies cited
above, particular stress was laid upon the ethnic background of
type 1 Gaucher disease patients. Wehave found that the rate of
inactivation of glucocerebrosidase by CBE in fibroblasts from
Discussion
The properties of the 370Asn -- Ser glucocerebrosidase in vitro
are intriguing: Under most assay conditions, this mutated en-
zyme is impaired in activity towards substrate. However, in the
presence of the natural activator protein saposin C and phos-
phatidylserine, the enzyme functions in a near normal fashion
at an appropriate acidic pH. To obtain information on the
properties of this mutated enzyme in situ, the irreversible inhib-
itor CBEhas been used, an approach that was developed and
used previously by other investigators (25, 36, 37). Although it
is obvious that the reaction of glucocerebrosidase with CBE
involves only part of the total reaction mechanism of substrate
hydrolysis (discussed in more detail in [2 ]), analysis of CBE-
induced inactivation of glucocerebrosidase is informative be-
cause the reactivity of (mutant) glucocerebrosidase with CBE
appears to reflect to a large extent the ability of enzyme to be
active towards substrate.
Table V. Level Qf Activator Protein (Saposin C) in Fibroblasts
and Lymphoblasts from a Control Subject
and a Type 1 Gaucher Patient
Cell type Cell line Activator
ULing protein
Fibroblasts Control 0.58
Type 1 Gaucher 0.53
Lymphoblasts Control 0.21
Type 1 Gaucher 0.26
Cell extracts were boiled for 5 min, centrifuged, and the supernatants
were tested for their capacity to stimulate the enzymic activity of
purified placental glucocerebrosidase as described (12). 1 U of activa-
tion is defined as the amount of activator protein that stimulates the
activity of glucocerebrosidase by a factor of 100.
Figure 3. Immunocytochemical visualisation of glucocerebrosidase and saposin C. Fibroblasts and lymphoblasts of a control subject and a
Gaucher disease type 1 patient heterozygous for the 370Asn -> Ser and 44Leu -* Pro glucocerebrosidase substitutions were washed in PBS, fixed,
cryosectioned and processed for immunogold double labeling as described (33). The immunoglobulins were visualized with protein A conjugated
with 10-nm gold particles (antiglucocerebrosidase) and with protein A conjugated with 5-nm gold particles (anti-saposin C). Identical results
were obtained when glucocerebrosidase was visualized with a 5-nm gold probe and the activator protein was visualized with a 10-nm gold probe.
(A) Fibroblasts of the control subject; (B) fibroblasts of the Gaucher patient; (C) lymphoblasts of the control subject; and (D) lymphoblasts of
the Gaucher patient. Bar, 0.2 ,m.















Figure 4. Influence of pH on the properties of 370Asn Ser gluco-
cerebrosidase, purified from spleen. The effect of pH on the properties
of immunoaffinity purified control and 370Asn -- Ser glucocerebrosi-
dase in the presence of 10 ,g/ml phosphatidylserine and 2.4 ;g/ml
saposin Cwas determined. (A) The activity of glucocerebrosidase was
determined with 5 mM4-MU-,B-glucoside as substrate in the presence
of 50 mMacetate buffer (o, * ) or 50:100 mMcitric acid/sodium
phosphate buffer (A, A) varying in pH from 4.0 to 6.0. o and A, con-
trol; and A, 370Asn -- Ser/370Asn -- Ser. (B) The inactivation of
glucocerebrosidase by CBEwas determined in 50:100 mMcitric
acid/sodium phosphate buffer (pH range 4.0-6.0). Enzyme activity
was determined as described in the legend of Fig. 1. o, Control; .,
370Asn -. Ser/370Asn Ser.
370Asn Ser/ 370Asn -* Ser patients and, to a lesser extent, in
fibroblasts from the more frequently encountered patients het-
erozygous for this mutation, is slow. However, we were not able
to distinguish type 1 Gaucher disease patients with Ashkenazi
Jewish background from patients with non-Jewish background
on the basis of CBE-induced inactivation.
During this study, the important observation was made
that the activation state of glucocerebrosidase in the lysosomes
as measured in situ differs in fibroblasts and lymphoblasts.
This finding substantiates earlier studies carried out with ho-
mogenates from the two cell types (23). The cell-type-specific








Cells preincubated No additions Taurocholate/Triton
Cell type for 30 min with (A) X-100 (B) A/B
nmol/h
Fibroblasts No additions 79.6 153.2 0.52
25 mMNH4C1 57.2 159.1 0.36
Lymphoblasts No additions 10.0 14.1 0.71
25 mMNH4Cl 5.3 13.9 0.38
Cells were harvested, washed in PBS and homogenized in 10:20 mM
citric acid/sodium phosphate buffer, pH 4.0, by brief sonication.
Enzyme activity was measured in two reaction mixtures. The reaction
mixture without an added activator contained 100:200 mMcitric
acid/sodium phosphate, pH 4.0, and 5 mM4-MU-,B-glucoside. The
other reaction mixture contained 100:200 mMcitric acid/sodium
phosphate, pH 5.2, 0.1% (by volume) Triton X-100 and 0.2% (mass/
vol) sodium taurocholate as activators, and 5 mM4-MU-f3-glucoside.
Assays were performed in the absence and presence of 1 mMCBE
to determine the contribution of glucocerebrosidase to the total (3-
glucosidase activity. The results of a typical experiment are given.
Similar results were obtained in two other independent experiments.
glucocerebrosidase, the catalytic properties of which are so
strongly determined by the state of activation of the enzyme.
Our studies suggest that the intralysosomal pH determines
the state of activation of glucocerebrosidase. Again, this is par-
ticularly relevant for 370Asn -* Ser glucocerebrosidase: the acti-
vation of this mutant enzyme by activator protein is extraordi-
narily pH sensitive. Thus, a cell-type-specific difference in in-
tralysosomal pH could explain the difference in properties of
370Asn - Ser glucocerebrosidase in intact fibroblasts and lym-
phoblasts. Moreover, variability between individuals in intra-
lysosomal conditions may underlie the heterogeneity in sever-
ity of the clinical expression of Gaucher disease in individuals
with the same glucocerebrosidase genotype. In this connection,
it is of interest to mention that some homozygotes for the
370Asn -> Ser glucocerebrosidase mutation are not or only very
mildly affected clinically (8, 38), and that a strict correlation
between glucocerebrosidase genotype and Gaucher disease
clinical phenotype has not always been noted; e.g., see refer-
ence 39. In Gaucher disease, glucocerebroside accumulation is
restricted to macrophage-like cells, It will, therefore, be of inter-
est to establish the intralysosomal pH and the state of activa-
tion of glucocerebrosidase in macrophages from patients with




Figure 5. Influence of ammonia on inactivation of glucocerebrosidase
in intact cells by conduritol B-epoxide. Cells were preincubated for
30 min at 37°C in culture medium containing different concentra-
tions of NH4Cl. Next, 100 uMCBEwas added to the medium and
the cells were harvested immediately or 1 h later. Glucocerebrosidase
activity per milligram total cellular protein was determined as de-
scribed in the legend to Table III. The results of a typical experiment
are shown. Similar results were obtained in at least two independent
experiments. (A) Lymphoblasts; (B) fibroblasts. o, Control; *,
"70Asn -- Ser/370Asn -- Ser; A, "70Asn -- Ser/4"Leu -- Pro.
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